Cargando…
Characteristics of Patients with Diabetes Initiating Sodium Glucose Co-transporter-2 Inhibitors (SGLT2i): Real-World Results from Three Administrative Databases in Japan
INTRODUCTION: The aim of this study was to evaluate the characteristics of new users of sodium glucose co-transporter-2 inhibitors (SGLT2i) in comparison with those of new users of other oral antidiabetic drugs (OADs) using data retrieved from three administrative databases in Japan. METHODS: This s...
Autores principales: | Ito, Yuichiro, Van Schyndle, James, Nishimura, Takuya, Sugitani, Toshifumi, Kimura, Tomomi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437244/ https://www.ncbi.nlm.nih.gov/pubmed/30730037 http://dx.doi.org/10.1007/s13300-019-0577-7 |
Ejemplares similares
-
Drug Utilization Patterns in Patients with Diabetes Initiating Sodium Glucose Co-Transporter-2 Inhibitors (SGLT2i) in Japan: A Multi-Database Study (2014–2017)
por: Ito, Yuichiro, et al.
Publicado: (2019) -
Real-World Effectiveness of Sodium Glucose Co-Transporter-2 Inhibitors in Japanese Patients with Diabetes Mellitus
por: Ito, Yuichiro, et al.
Publicado: (2019) -
Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database
por: Nagasu, Hajime, et al.
Publicado: (2021) -
Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis
por: Kalra, Sanjay, et al.
Publicado: (2015) -
Reduction in cardiovascular disease events in patients with type 2 diabetes mellitus treated with a sodium–glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase‐4 inhibitor: A real‐world retrospective administrative database analysis in Japan
por: Kashiwagi, Atsunori, et al.
Publicado: (2022)